|
ГАЛОПЕРИДОЛА ДЕКАНОАТ (HALOPERIDOL DECANOATE)- аннотация
Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients Wen-Ho Chang, Shih-Ku Lin, Dong-Juiing Juang, Li-Ching Chen, Chih-Hsien Yang, Hsien-Yuan Lane, and Michael W. Jann. BIOL PSYCHIATRY 557-559pdf
Neuroleptic Malignant Syndrome and Severe Thrombocytopenia: Case Report and Literature Review Shareh O. ghani, Waqas Ahmed and Luis A. Marco. Annals of Clinicol Psychiatry, Vol 12, 1, 2000pdf
Rehospitalization Risk With Second-Generation and Depot Antipsychotics Robert R. Conley, Deanna L. Kelly, Pharm D, BCPP, Raymond Vc Live, Pharm D , BCPP, fnd Robert P. McMahon, PhD. Annals of Clinicol Psychiatry, Vol 15, 1, March 2003pdf
Reduced haloperidol haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics Weh-Ho Ghang, Shih-Ku Lin, Dong-Juiing Juang, Li-Chen Chen, Chih-Hsein Yang, Wei-Herng Hu, Ching-piao Chien, Yw Francis Lam and Michael W Jann. Neuro-Psychopharmacol. & Biol. Psychiat. 1993 Vol 17, 105-112.pdf
Neuroleptic management of schizophrenia a survey and commentary on Australian psychiatric practice Gordon Parker, Yim Lambert, John McGrath, Patrik McGorry, John Tillerpdf
Haloperidol plasma "threshold" levels for relapse prevention in schizophrenia: a study with galoperidol decanoate A.C Altamura, G.L. Tacchini, M. Maes. European Neuropsychopharmacology Supplement, 1995 55-58 / Elseverpdf
Haloperidol decanoate in chronic scgizophrenia: a study of 12 months with plasma levels C.A. Altamura, F. Colacurcio, M.C. Mauri, A.R. Moro and F.de Novellis. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1990 Vol 14, 25-35. pdf
Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate. Clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid Michel W. Jann, Fu-Chuan Wei, Hsin-Nan Lin, Ching Piao-Chien and Wen-Ho Chang. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1996 Vol 20, 73-86. pdf
Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate. N. Aymard, A. Viala, I. Stein and F. Capoli. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1995 Vol 19, 1119-1135. pdf
Health care utilization in pacients with schizophrenia maintained on atypical versus conventional antipsychotics Gary Remengton and Iliya Khramov. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 2001 Vol 25, 363-369. Elsever pdf
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia John M Kane, John M Davis, Nina Schooler, Stephen Marder, et al. The American Journal of Psychiatry. Washington: Apr 2002. Vol. 159, Iss. 4; p. 554 (7 pages) pdf
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate Svante Nyberg M.D., Lars Farde M.D., Ph.D., Christer Halldin, Ph.D., Marja-Liisa Dahl M.D., Ph.D., and Leif Bertilsson, Ph.D. The American Journal of Psychiatry. Washington: Feb 1995. Vol. 152, Iss. 2; p. 173 (7 pages) pdf
Intramuscular Preparations of Antipsychotics Uses and Relevance in Clinical Practice A.C. Altamura, F. Sassella, A. Santini, C. Montresor, S. Fumagalli, E. Mundo. Drugs 2003, vol 63 (5), pp 493-512pdf
Neuropsychological impairment in patients treated with depot neuroleptics:a longitudinal study E Tuninger, S Levander. Acta Psychiatrica Scandinavica Volume 104, Issue s408, Page 75-80, Nov 2001 pdf
|
